Intelligence · Clinical Development
Pipeline search results
Programs matching “breast-cancer” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 272 pipeline programs matching "breast-cancer" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
Trastuzumab
Mylan IRE Healthcare Limited
Breast Cancer
1 trial -
Trastuzumab Emtansine
Hoffmann-La Roche
Metastatic Breast Cancer
1 trial -
Trastuzumab and neratinib
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Early-stage Breast Cancer
1 trial -
Trastuzumab deruxtecan
AstraZeneca
Breast Cancer; HER2-positive; Metastatic
1 trial -
Trastuzumab deruxtecan
AstraZeneca
Advanced or Metastatic Breast Cancer
1 trial -
Trastuzumab emtansine
Hoffmann-La Roche
Breast Cancer
3 trials -
Zanidatamab
Jazz Pharmaceuticals Ireland Limited
Metastatic HER2-positive Breast Cancer
1 trial -
Zoledronic acid
Novartis Pharmaceuticals
Breast Cancer
1 trial -
cyclophosphamide
Partner Therapeutics Limited
Breast Cancer
1 trial -
exemestane
Partner Therapeutics Limited
Breast Cancer
1 trial -
intensity-modulated radiation therapy
United Therapeutics Europe Ltd
Breast Cancer
1 trial -
internal mammary nodal irradiation
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Breast Cancer
1 trial -
metformin hydrochloride
United Therapeutics Europe Ltd
Breast Cancer
1 trial -
neratinib
PUMA BIOTECHNOLOGY, INC.
HER2+ Metastatic Breast Cancer (MBC)
1 trial -
nivolumab
Bristol-Myers Squibb
Breast Cancer
1 trial -
non-pegylated liposomal doxorubicin
Teva Pharma GmbH
Tubular Breast Cancer Stage II
1 trial -
paclitaxel/anthracycline
The First People's Hospital of Lianyungang
Primary Breast Cancer
1 trial -
pegcyte
Biotech Pharmaceutical Co.,
Breast Cancer Female
1 trial -
pegfilgrastim
United Therapeutics Europe Ltd
Breast Cancer
1 trial -
trastuzumab
United Therapeutics Europe Ltd
Breast Cancer
1 trial -
vinflunine
Pierre Fabre Medicament
Breast Cancer
1 trial -
20170512
The First People's Hospital of Lianyungang
Triple-Negative Breast Cancer
1 trial -
AB-201
Artiva Biotherapeutics
Breast Cancer
1 trial -
ASCAPE-based follow-up strategy
ATOSSA THERAPEUTICS, INC.
Breast Cancer
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.